Adam J Ronk
Overview
Explore the profile of Adam J Ronk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santos R, Ilinykh P, Pietzsch C, Ronk A, Huang K, Kuzmina N, et al.
Cell Rep
. 2023 Oct;
42(10):113254.
PMID: 37858466
Ebola virus (EBOV) and Bundibugyo virus (BDBV) belong to the family Filoviridae and cause a severe disease in humans. We previously isolated a large panel of monoclonal antibodies from B...
2.
Ronk A, Lloyd N, Zhang M, Atyeo C, Perrett H, Mire C, et al.
Nat Commun
. 2023 Sep;
14(1):5603.
PMID: 37699929
Lassa virus is a member of the Arenaviridae family, which causes human infections ranging from asymptomatic to severe hemorrhagic disease with a high case fatality rate. We have designed and...
3.
Jayaprakash A, Ronk A, Prasad A, Covington M, Stein K, Schwarz T, et al.
Viruses
. 2023 Feb;
15(2).
PMID: 36851566
The Marburg and Ebola filoviruses cause a severe, often fatal, disease in humans and nonhuman primates but have only subclinical effects in bats, including Egyptian rousettes, which are a natural...
4.
Brouwer P, Antanasijevic A, Ronk A, Muller-Krauter H, Watanabe Y, Claireaux M, et al.
Cell Host Microbe
. 2022 Nov;
30(12):1759-1772.e12.
PMID: 36400021
The Lassa virus is endemic in parts of West Africa, and it causes hemorrhagic fever with high mortality. The development of a recombinant protein vaccine has been hampered by the...
5.
Chang M, Tomasovic L, Kuzmina N, Ronk A, Byrne P, Johnson R, et al.
Nat Commun
. 2022 Oct;
13(1):5814.
PMID: 36192374
Monoclonal antibodies are a promising approach to treat COVID-19, however the emergence of SARS-CoV-2 variants has challenged the efficacy and future of these therapies. Antibody cocktails are being employed to...
6.
Maisonnasse P, Aldon Y, Marc A, Marlin R, Dereuddre-Bosquet N, Kuzmina N, et al.
Nat Commun
. 2021 Oct;
12(1):6097.
PMID: 34671037
Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic...
7.
Malherbe D, Kurup D, Wirblich C, Ronk A, Mire C, Kuzmina N, et al.
NPJ Vaccines
. 2021 Jul;
6(1):91.
PMID: 34294728
The development of effective countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the COVID-19 pandemic, is a priority. We designed and produced ConVac, a replication-competent...
8.
Engdahl T, Kuzmina N, Ronk A, Mire C, Hyde M, Kose N, et al.
Cell Rep
. 2021 Jul;
36(3):109453.
PMID: 34289361
No abstract available.
9.
Engdahl T, Kuzmina N, Ronk A, Mire C, Hyde M, Kose N, et al.
Cell Rep
. 2021 May;
35(5):109086.
PMID: 33951434
New World hantaviruses (NWHs) are endemic in North and South America and cause hantavirus cardiopulmonary syndrome (HCPS), with a case fatality rate of up to 40%. Knowledge of the natural...
10.
Kurup D, Malherbe D, Wirblich C, Lambert R, Ronk A, Zabihi Diba L, et al.
PLoS Pathog
. 2021 Mar;
17(3):e1009383.
PMID: 33765062
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia,...